Procter & Gamble executive Ma. Fatima Francisco, CEO of the Baby, Fem & Family Care unit, reported a sale of 8,000 shares of common stock on 02/04/2026 at $158 per share. After this sale, she directly holds 6,571.1998 shares of P&G common stock.
She also reports indirect holdings of 16,139.3909 shares through a retirement plan trustee, 2,898.8166 shares held by her spouse and retirement plan trustees, and 12,731 shares held by a SLAT. A footnote states one position reflects an adjustment to PST through December 31, 2025.
The Procter & Gamble Company shareholder filed a notice to sell 72,186 shares of common stock, with an aggregate market value of $11,007,643.14.
The shares are to be sold through Morgan Stanley Smith Barney LLC on the NYSE around February 4, 2026, and were acquired that same day by exercising a stock option for cash. Shares outstanding were 2,324,000,685 common shares at the time referenced.
The Procter & Gamble Company has an affiliated holder filing a Rule 144 notice to sell up to 13,549 shares of common stock through Fidelity Brokerage Services on the NYSE, with an approximate sale date of 01/29/2026 and an aggregate market value of $2,015,887.97.
These shares relate to a prior restricted stock unit award of 18,412 common shares acquired on 10/01/2020 from The Procter & Gamble Company, with cash as the form of payment. Shares outstanding were 2,324,000,685 at the time referenced. The seller represents they know no undisclosed material adverse information about the issuer.
Procter & Gamble Chief Brand Officer Marc S. Pritchard reported an option exercise and share sale in Procter & Gamble common stock on January 23, 2026. He exercised a stock option for 95,903 shares at an exercise price of $80.29 per share, then sold 95,903 shares of common stock at a weighted average price of $151.1495 per share, within a price range of $150.36 to $151.60. Following these transactions, he directly owned 182,606.5502 shares of Procter & Gamble common stock, with additional indirect holdings through his daughters, retirement plan trustees, and his wife.
The Procter & Gamble Company reports steady results for the three and six months ended December 31, 2025, with modest sales growth but some margin pressure. For the three-month period, net sales rose to $22.2 billion from $21.9 billion (up about 1%), while net earnings declined to $4.3 billion from $4.7 billion and diluted EPS slipped to $1.78 from $1.88 as gross margin and operating margin narrowed due to unfavorable mix, higher tariffs, product and packaging investments and higher restructuring costs.
Over six months, net sales increased to $44.6 billion from $43.6 billion (2% growth), net earnings rose to $9.1 billion from $8.6 billion (5% growth) and diluted EPS grew 7% to $3.73. Core EPS, which excludes incremental restructuring, was $3.87, up 2%. Operating margin eased to 25.2% as higher restructuring and tariff costs outweighed productivity savings and pricing. Operating cash flow reached $10.4 billion, with adjusted free cash flow of $8.7 billion and adjusted free cash flow productivity of 95%, while the company continued significant restructuring and recorded strong contributions from Beauty, Grooming and Health Care segments.
The Procter & Gamble Company security holder has filed a notice of intent to sell 95,903 shares of common stock. The shares are expected to be sold on or about 01/23/2026 on the NYSE through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $14,018,141.51.
The planned sale is tied to the exercise and sale of stock options, with the options acquired and paid in cash on 01/23/2026. The filing notes that Procter & Gamble had 2,336,733,549 shares outstanding, which is a baseline figure, not the amount being sold.
The Procter & Gamble Company filed a current report to share that it issued a press release announcing its second quarter results and held a related conference call. The company is also making available a set of informational slides that were referenced on the call and posted on its website.
This report is furnished under Regulation FD, which is meant to ensure all investors have access to the same information at the same time. The filing also lists the company’s common stock and various outstanding debt securities that are registered for trading on the New York Stock Exchange.
The Procter & Gamble Company filed a current report to furnish its latest quarterly earnings release. The company issued a news release covering results for the quarter ended December 31, 2025, and is providing this report under the “Results of Operations and Financial Condition” item.
The filing identifies Procter & Gamble’s common stock and multiple series of notes listed on the NYSE and attaches the earnings news release as an exhibit. This report serves mainly as a formal SEC submission of the previously issued earnings information.
The Procter & Gamble Company disclosed that its Board of Directors declared a quarterly dividend of $1.0568 per share on its Common Stock and on its Series A and Series B ESOP Convertible Class A Preferred Stock. The dividend is payable on or after February 17, 2026 to Common Stock shareholders of record at the close of business on January 23, 2026, and to the ESOP preferred shareholders of record at the start of business on the same date. This filing simply reports the Board’s latest dividend decision under Regulation FD.
The Procter & Gamble Company disclosed that Jennifer Davis, currently Chief Executive Officer - Health Care, has notified the company of her intent to retire. The notice was given on December 9, 2025, and her retirement is expected to be effective June 30, 2026.
Davis is retiring after more than 33 years of service with Procter & Gamble, reflecting a long tenure in senior leadership. The filing does not provide additional details on succession or changes to the company’s broader strategy.